As of September 30, 2025, Corvus had cash, cash equivalents and marketable securities of $65.7 million as compared to $52.0 million as of December 31, 2024. Consistent with last quarter, Corvus ...
MIT engineers have developed a flexible drug-delivery patch that can be placed on the heart after a heart attack to help ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), announced that Nanoviricides CEO Dr Anil Diwan joined ...
Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease 2, at a late-breaker presentation during the American ...
WEST PALM BEACH, FL – October 21, 2025 – PRESSADVANTAGE – All In Solutions Wellness Center, a Joint Commission-accredited ...
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...
The FDA has approved a new single-injection, once-monthly maintenance regimen for Eli Lilly’s Omvoh (mirikizumab-mrkz), ...
CESSA Phase 3 Clinical Trial Results Earn ACG Presidential Poster Distinction Among Nearly 6,000 Abstracts Next-generation Hydrocortisone Acetate (ngHCA™) ...
The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain ...
WhiteSands Alcohol & Drug Rehab has released a new online resource, “Access Support for Families of Drug Addicts“, available ...
A review of recent literature shows bioengineering is reshaping oncology, from synthetic biology to nanomedicine, but what's ...
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback